Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia

D. Agapakis, D. Tsantilas, P. Psarris, E. Massa, P. Kotsaftis, K. Tziomalos, A. Hatzitolios (Thessaloniki, Greece)

Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Session: The prognosis of community-acquired pneumonia: old and new markers of severity
Session type: E-Communication Session
Number: 2212
Disease area: Respiratory infections

Congress or journal article abstractE-poster

Rating: 0
You must login to grade this presentation.

Share or cite this content

Citations should be made in the following way:
D. Agapakis, D. Tsantilas, P. Psarris, E. Massa, P. Kotsaftis, K. Tziomalos, A. Hatzitolios (Thessaloniki, Greece). Admission CRP and D-dimer levels can identify high-risk patients with community-acquired pneumonia. Eur Respir J 2010; 36: Suppl. 54, 2212

You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.

Member's Comments

No comment yet.
You must Login to comment this presentation.


Related content which might interest you:
Predictive value of plasma D-dimer in patients with community-acquired pneumonia (CAP)
Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity
Year: 2010


High serum procalcitonin and C-reactive protein levels can exclude tuberculosis in community-acquired pneumonia patients with atypical presentation
Source: Annual Congress 2010 - Aetiology of lower respiratory tract infections and treatment in special situations
Year: 2010


Procalcitonin and D-dimer to predict prognosis and clinical outcomes in severe community-acquired pneumonia (SCAP) patients
Source: Annual Congress 2012 - Respiratory infections: a clinical point of view
Year: 2012


Diagnostic and prognostic value of C-reactive protein in community-acquired pneumonia hospitalized patients
Source: Eur Respir J 2004; 24: Suppl. 48, 188s
Year: 2004

C-reactive protein as severity biomarker in patients with community-acquired pneumonia (CAP)
Source: Eur Respir J 2005; 26: Suppl. 49, 545s
Year: 2005

Admission glucose concentrations independently predict early mortality in patients with community-acquired pneumonia
Source: Eur Respir J 2007; 30: Suppl. 51, 482s
Year: 2007

Pro-adrenomedullin, procalcitonin and CRP levels to predict bacterial pneumonia in patients admitted to emergency room
Source: Annual Congress 2011 - Biomarkers and outcomes of community-acquired pneumonia
Year: 2011

Usefulness of C-reactive protein and procalcitonin in predicting mortality in community-acquired pneumonia
Source: Annual Congress 2008 - Factors related to outcome of community-acquired pneumonia
Year: 2008


Determining the prognostic value of procalcitonin in ICU patients who developed hospital acquired pneumonia and comparing with sencitive CRP
Source: Annual Congress 2009 - Impact of biomarkers in the management of community-acquired pneumonia
Year: 2009


Prognostic value of plasma D-dimer level in adults with community-acquired pneumonia – A prospective study
Source: International Congress 2015 – CAP: prognostic factors in frail patients
Year: 2015


Usefulness of consecutive C-reactive protein measurements in follow-up of severe community-acquired pneumonia
Source: Eur Respir J 2008; 32: 726-732
Year: 2008



Diagnostic and prognostic utility of procalcitonin (PCT) measurements in patients with hospitalized community-acquired pneumonia (CAP)
Source: Annual Congress 2009 - Assessment of severity in respiratory infections: severity scales and biomarkers
Year: 2009

Procalcitonin predicts patients at low risk of death from community-acquired pneumonia across all CRB-65 groups at risk
Source: Eur Respir J 2007; 30: Suppl. 51, 481s
Year: 2007

Serum procalcitonin and C-reactive protein in children with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 488s
Year: 2006

Individual monitoring of procalcitonin and C-reactive protein levels as a criterion for cancel of antibiotic therapy in patients with severe community-acquired pneumonia
Source: Annual Congress 2013 –Biomarkers, diagnosis and outcome of respiratory infections
Year: 2013


Serum procalcitonin (PCT) as a marker of the severity and prognosis of ventilator-associated pneumonia (VAP)
Source: Annual Congress 2007 - Diagnostic markers and therapy in hospital-acquired pneumonia
Year: 2007


CRP and ESR as discharged criteria of patients admitted with community-acquired pneumonia
Source: Eur Respir J 2006; 28: Suppl. 50, 374s
Year: 2006

Serum procalcitonin and community-acquired pneumonia in childhood
Source: Eur Respir J 2005; 26: Suppl. 49, 167s
Year: 2005

The influence of prednisolone on C-reactive protein and procalcitonin in patients hospitalised with community-acquired pneumonia
Source: Annual Congress 2010 - Risk factors and outcomes in community-acquired pneumonia
Year: 2010


Serum KL-6 elevation related with severity in patients with pneumocystis pneumonia
Source: Annual Congress 2011 - Infection in the immunocompromised host: infrequent aetiologies
Year: 2011